News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Employee Blows Whistle on Drug Promotions


11/12/2012 7:33:02 AM

At a time when GlaxoSmithKline execs have been arguing that off-label promotional activity is no longer standard operating procedure, they must have been chagrined to learn that a Glaxo employee earlier this year complained to the UK trade group for the pharmaceutical industry that promotional and training efforts involving sales reps crossed the line. In a ruling issued last week, the Association for the British Pharmaceutical Industry found that Glaxo violated the code of conduct three different ways in connection with a promotional push for the Revolade treatment for a rare bleeding disorder known as immune thrombocytopenic purpura, or ITP. The unnamed Glaxo (GSK) employee complained that a sales rep had promoted Revolade for myeloid fibrosis to an National Health Service consultant through e-mails and meetings. And the panel ruled that the communications, which referred to both maladies involving a particular patient, could have been misconstrued and the rep should have known better.

Read at Pharmalot


comments powered by Disqus
Pharmalot
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES